Key result
Palliative radiotherapy and eribulin chemotherapy provided temporary tumor shrinkage and symptom relief for unresectable primary duodenal dedifferentiated liposarcoma, but the patient died at 9 months.
Case Report (n=1)
Multimodal therapy with radiotherapy and eribulin can provide temporary symptom relief and tumor control in unresectable primary duodenal dedifferentiated liposarcoma, though long-term prognosis remains poor.
Radiotherapy plus eribulin may temporarily palliate unresectable duodenal liposarcoma; leaves open this approach in rare gastrointestinal sites.
A 51-year-old woman presented with syncope and gastrointestinal bleeding. Imaging revealed a 7-cm duodenal mass with mesenteric and pancreatic involvement. An endoscopic biopsy confirmed dedifferentiated liposarcoma. She received palliative radiotherapy to control bleeding, followed by eribulin-based chemotherapy, which temporarily shrank the tumor and allowed discontinuation of parenteral nutrition. Additional radiotherapy did not prevent disease progression, and chemotherapy was discontinued. The patient died nine months after the diagnosis. This rare case highlights the challenges of managing unresectable primary duodenal dedifferentiated liposarcoma but suggests that radiotherapy and systemic therapy can provide temporary control and symptom relief.
No takes yet. Share an insight, caveat, or question.
Noguchi et al. (2025) conducted a case report in Primary Dedifferentiated Liposarcoma of the Duodenum (n=1). Radiotherapy and eribulin chemotherapy was evaluated on Tumor response and survival. Palliative radiotherapy and eribulin chemotherapy provided temporary tumor shrinkage and symptom relief for unresectable primary duodenal dedifferentiated liposarcoma, but the patient died at 9 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: